Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024

Estrella Immunopharma, Inc.

Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.
Transition period covers July 1, 2024 through December 31, 2024.
Company will file Form 10-KT with audited financials for the transition period.

item 5.03 item 9.01

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-102899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.